Exane Derivatives’s Guardant Health GH Stock Holding History

Exane Derivatives’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$2.78K	Sell	69 -815	-92%	-$40.4K	﹤0.01%	415
2022 Q1	$58.6K	Sell	884 -177	-17%	-$12.1K	0.02%	554
2021 Q4	$106K	Sell	1,061 -1,405	-57%	-$145K	0.03%	435
2021 Q3	$308K	Sell	2,466 -226	-8%	-$26.9K	0.07%	282
2021 Q2	$326K	Sell	2,692 -522	-16%	-$70.2K	0.07%	263
2021 Q1	$491K	Sell	3,214 -1,394	-30%	-$211K	0.14%	149
2020 Q4	$594K	Buy	4,608 +2,878	+166%	+$331K	0.17%	122
2020 Q3	$193K	Buy	+1,730	New	+$158K	0.06%	210

Other funds holding GH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Exane Derivatives's GH Position: Q2 2022 in Review

Exane Derivatives reduced its Guardant Health (GH) stake by 92% in Q2 2022, selling an estimated $40.4K and leaving 69 shares worth $2.78K. The position accounts for ﹤0.01% of the portfolio, ranked #415.

Exane Derivatives first reported a position in GH in Q3 2020 and has held it in 8 quarters since. The position peaked at $594K in Q4 2020. 332 funds tracked by Wall St. Rank hold GH as of Q2 2022.

Exane Derivatives held 69 shares of Guardant Health worth $2.78K as of Q2 2022.
Exane Derivatives sold 815 Guardant Health shares in Q2 2022, an estimated $40.4K.
Guardant Health made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #415 holding.
Exane Derivatives first reported a position in Guardant Health in Q3 2020 and has held it in 8 quarters since.
Exane Derivatives's Guardant Health position peaked at $594K in Q4 2020.
332 funds tracked by Wall St. Rank held Guardant Health as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.